Suggestions
Matthew Segall
CEO at Optibrium Ltd.
Matthew Segall is the CEO of Optibrium Ltd., a company based in the Greater Cambridge Area that specializes in developing software for drug discovery.1 He has held this position since May 2009 when the company was founded as a spin-out of BioFocus DPI.1
Education and Early Career
Segall has a strong academic background in science and computation:
- PhD in Theoretical Physics from the University of Cambridge (1994-2000)
- MSc in Computation from the University of Oxford (1990-1994)
- Attended St. Albans School (1982-1990)1
After completing his PhD, Segall worked as a Postdoctoral Research Associate at the Cavendish Laboratory, University of Cambridge, from 1997 to 2001.1
Professional Experience
Before founding Optibrium, Segall held several leadership positions in the pharmaceutical and biotechnology industries:
- Senior Director of ADMET at BioFocus DPI (2006-2009)
- Head of Admensa Business Unit at Inpharmatica Ltd (2006)
- Associate Director at Inpharmatica Ltd (2003-2005)
- Associate Director at ArQule (2002-2003)
- Assistant Director of Quantum Simulation at Camitro (2001-2002)1
Optibrium Ltd.
As CEO of Optibrium, Segall leads a company dedicated to providing software that guides decisions involving complex, uncertain data in drug discovery. Their primary product, StarDrop, helps scientists design and select potential drug molecules.1 Under his leadership, Optibrium has developed a global customer base, serving top pharmaceutical companies, small biotechs, and academic groups.1
Expertise and Contributions
Segall has extensive experience in developing predictive ADME (Absorption, Distribution, Metabolism, and Excretion) models and decision-support tools for drug discovery.2 He has published over 30 peer-reviewed papers and book chapters on computational chemistry, cheminformatics, and drug discovery.2 His work focuses on using artificial intelligence and machine learning to improve drug discovery processes, particularly in the area of deep learning imputation for filling in missing data in pharmaceutical research.3
